![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more
GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical...
GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its...
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyās management team will...
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT PR Newswire NEW YORK, June 20, 2024 NEW YORK, June 20...
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT PR Newswire NEW YORK, June 17, 2024 NEW YORK, June 17, 2024 /PRNewswire/...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT PR Newswire NEW YORK, June 10, 2024 NEW YORK, June 10, 2024 /PRNewswire/...
Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with...
Period ā | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.125 | 18.4275184275 | 6.105 | 6.755 | 5.64 | 5092807 | 6.18831864 | CS |
4 | -0.24 | -3.21285140562 | 7.47 | 7.9399 | 5.64 | 3020087 | 6.57366049 | CS |
12 | -3.02 | -29.4634146341 | 10.25 | 11.01 | 5.64 | 3021471 | 7.4450328 | CS |
26 | -2.31 | -24.213836478 | 9.54 | 14.84 | 5.64 | 4876950 | 9.712946 | CS |
52 | 3.31 | 84.4387755102 | 3.92 | 14.84 | 2.09 | 4785316 | 7.4330123 | CS |
156 | -8.91 | -55.2044609665 | 16.14 | 23.49 | 2.09 | 2633034 | 8.58780017 | CS |
260 | 4.95 | 217.105263158 | 2.28 | 35.1 | 1.45 | 2225852 | 9.95453945 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions